ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-β

Upon treatment with protein therapeutics, a subset of patients will typically develop antibodies against the drug. These anti-drug antibodies can be of concern because they have the potential to alter the drug's therapeutic activity. In the case of relapsing-remitting multiple sclerosis (RRMS)...

Ausführliche Beschreibung